Investment
Features
FeesSafety
Academy
More
Pluang+

Compare VanEck Uranium & Nuclear ETF (NLR) vs 10X Genomics Inc (TXG) Price & Performance

VanEck Uranium & Nuclear ETFTrade
10X Genomics IncTrade

Price performance (Past 24H)

Key statistics

VanEck Uranium & Nuclear ETF vs 10X Genomics Inc — how do they compare? VanEck Uranium & Nuclear ETF trades at $103 (market cap $3.51B), while 10X Genomics Inc trades at $78.76 (market cap $10.07B). The key difference: 10X Genomics Inc is far larger — about 2.9× VanEck Uranium & Nuclear ETF's market cap, and 10X Genomics Inc is trading nearer its 52-week high, VanEck Uranium & Nuclear ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold VanEck Uranium & Nuclear ETF for 7 Days and 10X Genomics Inc for 92 Days on average.

NLRTXG
Market Cap
$3.51B$10.07B
Volume
414,5165,657,286
Sector
Sector/ThematicHealth
52-Week High
$164.37$97.74
52-Week Low
$102.38$11.48
Typical Hold Time
7 Days92 Days
Enterprise Value
—$9.59B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

VanEck Uranium & Nuclear ETF

No Aura AI signal available yet.

10X Genomics Inc

10x Genomics (TXG) trades at $76.10, down 5.65% on the day, as technical indicators signal bearish momentum with the stock below key resistance levels. The company shows improving fundamentals with three consecutive quarterly earnings beats and positive operating cash flow of $136M in 2025, though it remains unprofitable with a -12.18% net margin. Recent developments include the launch of Atera spatial biology platform shipments and a patent victory against Parse Biosciences.

TXG presents a mixed investment case with strong product innovation and improving financial trends offset by high valuation metrics and persistent losses. The stock's risk/reward appears balanced near analyst consensus targets, requiring successful execution on Atera commercialization and path to profitability to justify current multiples.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

NLR
9% Buy91% Sell
Avg holding period · 7 Days
TXG
4% Buy96% Sell
Avg holding period · 92 Days

Top news

Latest headlines on both assets

About VanEck Uranium & Nuclear ETF

VanEck Uranium and Nuclear ETF seeks exposure to companies involved in uranium mining and the nuclear power industry. Its holdings may include miners, utilities, reactor-related companies, and nuclear equipment or service providers.

Read more on NLR →

About 10X Genomics Inc

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.

Read more on TXG →